- Home
- AIDX vs BOLT Comparison
AIDX vs BOLT Comparison
Compare AIDX & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIDX | BOLT |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 10.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AIDX | BOLT |
|---|---|---|
| Price | $0.58 | $3.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | ★ 445.8K | 30.8K |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,695,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $133.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.07 |
| 52 Week Low | $0.51 | $3.75 |
| 52 Week High | $14.09 | $7.20 |
Technical Indicators
Market Signals| Indicator | AIDX | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 36.20 | 40.31 |
| Support Level | $0.52 | $3.90 |
| Resistance Level | $0.70 | $5.05 |
| Average True Range (ATR) | 0.06 | 0.30 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 42.09 | 26.19 |
Price Performance
Historical ComparisonAbout AIDX 20/20 Biolabs Inc. Common Stock
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.